Pasireotide Diaspartate




Pasireotide Diaspartate Overview

Pasireotide (SOM230, trade name Signifor[2]) is an orphan drug approved in the United States[3] and Europe[4] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.[5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Pasireotide was approved for Cush...

Read more Pasireotide Diaspartate Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pasireotide

Recent Pasireotide Diaspartate Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pasireotide Diaspartate
  • For Suspension: 10mg/vial, 20mg/vial, 30mg/vial, 40mg/vial, 60mg/vial
  • Injection: 0.3mg/1ml, 0.6mg/1ml, 0.9mg/1ml
  • Powder: 20mg/vial, 40mg/vial, 60mg/vial
  • Solution: 0.3mg/ml (0.3mg/ml), 0.6mg/ml (0.6mg/ml), 0.9mg/ml (0.9mg/ml)
  • Suspension: 20mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Pasireotide Diaspartate or a similar ingredient: (2 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 September 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA